Pinnacle Bancorp Inc. Sells 6,896 Shares of Pfizer Inc. (NYSE:PFE)

Pinnacle Bancorp Inc. cut its stake in Pfizer Inc. (NYSE:PFE) by 25.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 19,695 shares of the biopharmaceutical company’s stock after selling 6,896 shares during the period. Pinnacle Bancorp Inc.’s holdings in Pfizer were worth $523,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Lmcg Investments LLC lifted its holdings in Pfizer by 1.1% during the 2nd quarter. Lmcg Investments LLC now owns 51,777 shares of the biopharmaceutical company’s stock valued at $1,449,000 after purchasing an additional 543 shares during the last quarter. Pekin Hardy Strauss Inc. boosted its holdings in shares of Pfizer by 8.4% in the 2nd quarter. Pekin Hardy Strauss Inc. now owns 27,095 shares of the biopharmaceutical company’s stock worth $758,000 after acquiring an additional 2,090 shares in the last quarter. Edgestream Partners L.P. increased its holdings in Pfizer by 1,704.3% during the 2nd quarter. Edgestream Partners L.P. now owns 157,967 shares of the biopharmaceutical company’s stock valued at $4,420,000 after purchasing an additional 149,212 shares in the last quarter. Perennial Investment Advisors LLC boosted its stake in Pfizer by 9.6% in the second quarter. Perennial Investment Advisors LLC now owns 15,549 shares of the biopharmaceutical company’s stock worth $435,000 after purchasing an additional 1,358 shares in the last quarter. Finally, Lumbard & Kellner LLC raised its holdings in shares of Pfizer by 8.0% in the second quarter. Lumbard & Kellner LLC now owns 113,901 shares of the biopharmaceutical company’s stock valued at $3,187,000 after buying an additional 8,454 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Truist Financial decreased their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Bank of America reissued a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Finally, Guggenheim cut their price target on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Insider Activity at Pfizer

In other news, Director Scott Gottlieb purchased 1,000 shares of the company’s stock in a transaction on Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the transaction, the director now owns 10,000 shares of the company’s stock, valued at $282,400. The trade was a 11.11 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.06% of the stock is owned by company insiders.

Pfizer Stock Down 0.6 %

Shares of PFE stock opened at $26.25 on Thursday. The firm’s fifty day moving average price is $26.13 and its two-hundred day moving average price is $28.03. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The firm has a market capitalization of $148.76 billion, a P/E ratio of 35.47, a PEG ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. During the same quarter in the previous year, the business earned ($0.17) earnings per share. Pfizer’s quarterly revenue was up 31.2% on a year-over-year basis. On average, equities analysts predict that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.55%. The ex-dividend date is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is presently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.